File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells

TitleContext-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells
Authors
KeywordsBRAFV600E
Context-dependency
ERK pathway
Melanoma
MiR-204 family
Issue Date2017
Citation
Oncotarget, 2017, v. 8, n. 15, p. 25395-25417 How to Cite?
AbstractDespite increasing amounts of experimental evidence depicting the involvement of non-coding RNAs in cancer, the study of BRAFV600E-regulated genes has thus far focused mainly on protein-coding ones. Here, we identify and study the microRNAs that BRAFV600E regulates through the ERK pathway. By performing small RNA sequencing on A375 melanoma cells and a vemurafenibresistant clone that was taken as negative control, we discover miR-204 and miR-211 as the miRNAs most induced by vemurafenib. We also demonstrate that, although belonging to the same family, these two miRNAs have distinctive features. miR-204 is under the control of STAT3 and its expression is induced in amelanotic melanoma cells, where it acts as an effector of vemurafenib's anti-motility activity by targeting AP1S2. Conversely, miR-211, a known transcriptional target of MITF, is induced in melanotic melanoma cells, where it targets EDEM1 and consequently impairs the degradation of TYROSINASE (TYR) through the ER-associated degradation (ERAD) pathway. In doing so, miR-211 serves as an effector of vemurafenib's pro-pigmentation activity. We also show that such an increase in pigmentation in turn represents an adaptive response that needs to be overcome using appropriate inhibitors in order to increase the efficacy of vemurafenib. In summary, we unveil the distinct and context-dependent activities exerted by miR-204 family members in melanoma cells. Our work challenges the widely accepted "same miRNA family = same function" rule and provides a rationale for a novel treatment strategy for melanotic melanomas that is based on the combination of ERK pathway inhibitors with pigmentation inhibitors.
Persistent Identifierhttp://hdl.handle.net/10722/318658
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorVitiello, Marianna-
dc.contributor.authorTuccoli, Andrea-
dc.contributor.authorD'Aurizio, Romina-
dc.contributor.authorSarti, Samanta-
dc.contributor.authorGiannecchini, Laura-
dc.contributor.authorLubrano, Simone-
dc.contributor.authorMarranci, Andrea-
dc.contributor.authorEvangelista, Monica-
dc.contributor.authorPeppicelli, Silvia-
dc.contributor.authorIppolito, Chiara-
dc.contributor.authorBarravecchia, Ivana-
dc.contributor.authorGuzzolino, Elena-
dc.contributor.authorMontagnani, Valentina-
dc.contributor.authorGowen, Michael-
dc.contributor.authorMercoledi, Elisa-
dc.contributor.authorMercatanti, Alberto-
dc.contributor.authorComelli, Laura-
dc.contributor.authorGurrieri, Salvatore-
dc.contributor.authorWu, Lawrence W.-
dc.contributor.authorOpe, Omotayo-
dc.contributor.authorFlaherty, Keith-
dc.contributor.authorBoland, Genevieve M.-
dc.contributor.authorHammond, Marc R.-
dc.contributor.authorKwong, Lawrence-
dc.contributor.authorChiariello, Mario-
dc.contributor.authorStecca, Barbara-
dc.contributor.authorZhang, Gao-
dc.contributor.authorSalvetti, Alessandra-
dc.contributor.authorAngeloni, Debora-
dc.contributor.authorPitto, Letizia-
dc.contributor.authorCalorini, Lido-
dc.contributor.authorChiorino, Giovanna-
dc.contributor.authorPellegrini, Marco-
dc.contributor.authorHerlyn, Meenhard-
dc.contributor.authorOsman, Iman-
dc.contributor.authorPoliseno, Laura-
dc.date.accessioned2022-10-11T12:24:16Z-
dc.date.available2022-10-11T12:24:16Z-
dc.date.issued2017-
dc.identifier.citationOncotarget, 2017, v. 8, n. 15, p. 25395-25417-
dc.identifier.urihttp://hdl.handle.net/10722/318658-
dc.description.abstractDespite increasing amounts of experimental evidence depicting the involvement of non-coding RNAs in cancer, the study of BRAFV600E-regulated genes has thus far focused mainly on protein-coding ones. Here, we identify and study the microRNAs that BRAFV600E regulates through the ERK pathway. By performing small RNA sequencing on A375 melanoma cells and a vemurafenibresistant clone that was taken as negative control, we discover miR-204 and miR-211 as the miRNAs most induced by vemurafenib. We also demonstrate that, although belonging to the same family, these two miRNAs have distinctive features. miR-204 is under the control of STAT3 and its expression is induced in amelanotic melanoma cells, where it acts as an effector of vemurafenib's anti-motility activity by targeting AP1S2. Conversely, miR-211, a known transcriptional target of MITF, is induced in melanotic melanoma cells, where it targets EDEM1 and consequently impairs the degradation of TYROSINASE (TYR) through the ER-associated degradation (ERAD) pathway. In doing so, miR-211 serves as an effector of vemurafenib's pro-pigmentation activity. We also show that such an increase in pigmentation in turn represents an adaptive response that needs to be overcome using appropriate inhibitors in order to increase the efficacy of vemurafenib. In summary, we unveil the distinct and context-dependent activities exerted by miR-204 family members in melanoma cells. Our work challenges the widely accepted "same miRNA family = same function" rule and provides a rationale for a novel treatment strategy for melanotic melanomas that is based on the combination of ERK pathway inhibitors with pigmentation inhibitors.-
dc.languageeng-
dc.relation.ispartofOncotarget-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectBRAFV600E-
dc.subjectContext-dependency-
dc.subjectERK pathway-
dc.subjectMelanoma-
dc.subjectMiR-204 family-
dc.titleContext-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells-
dc.typeArticle-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.18632/oncotarget.15915-
dc.identifier.pmid28445987-
dc.identifier.pmcidPMC5421939-
dc.identifier.scopuseid_2-s2.0-85017567482-
dc.identifier.volume8-
dc.identifier.issue15-
dc.identifier.spage25395-
dc.identifier.epage25417-
dc.identifier.eissn1949-2553-
dc.identifier.isiWOS:000399340300114-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats